On September 26, 2025, Predictive Oncology Inc. (NASDAQ: POAI) announced a 1‑for‑15 reverse stock split that will become effective at 12:01 a.m. on Tuesday, September 30, 2025. The split will reduce the company’s outstanding shares from 11,436,201 to 762,414, with fractional shares rounded up to the nearest whole share. The new CUSIP for the common stock will be 74039M408.
The reverse split is intended to bring POAI into compliance with Nasdaq Capital Market’s minimum bid price requirement and to prevent a potential delisting. The action will not alter any shareholder’s percentage ownership except for rounding adjustments, and all equity awards, convertible preferred stock, and warrants will be proportionally adjusted. The company’s stock will continue to trade under the symbol POAI on Nasdaq after the split.
The decision follows a special meeting of shareholders on September 19, 2025, where the amendment to the certificate of incorporation was approved. By executing the reverse split, POAI aims to maintain its Nasdaq listing and preserve its ability to raise capital, which is critical given the company’s ongoing liquidity challenges.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.